Sanolium AB – Approval of written procedure

Sanolium AB (publ) (the "Company" and together with its subsidiaries the "Group") today announces the successful completion of the written procedure that was initiated on 17 June 2026 (the "Written Procedure") in relation to the Company's up to SEK 1,500,000,000 senior secured callable floating rate bonds with ISIN SE0021628237 (the "Bonds").

The Issuer has requested that holders of the Bonds to vote in favour of a temporary increase of the commitments under the revolving facility under the Company's super senior facility agreement and a corresponding temporary increase of the super senior headroom under the intercreditor agreement, as further specified in the notice of the written procedure (the "Request").

Please read more in the attached document.

For further information, please contact: 

Rami Avidan
CEO
+46 070 793 483 
rami.avidan@cambio.se

Johannes Fabó
CFO
+46 730 599 368
johannes.fabo@cambio.se

Sanolium AB, parent of the Cambio Group (“Cambio” or “the Company”) operating entities, is an e-health company providing comprehensive IT solutions to improve healthcare and patient safety. Cambio is one of the largest suppliers in Scandinavia and a growing player in the European market, with more than 170,000 users across regions and municipalities, general and university hospitals, health centers and specialist units. Cambio has offices in Sweden, Denmark, United Kingdom and Sri Lanka.